Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study.~2. Female subjects must not be pregnant.~3. Have one of the following clinical diagnoses for at least 3 months prior to screening: Schizophrenia or Schizoaffective Disorder, or Mood Disorder.~4. Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months prior to screening.~5. Have moderate or severe TD.~6. If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or mood disorder, be on stable doses.~7. Be in good general health.~8. Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.~9. Have a negative drug screen for amphetamines,barbiturates, benzodiazepines, phencyclidine, cocaine, opiates, or cannabinoids~Exclusion Criteria:~1. Have an active, clinically significant unstable medical condition within 1 month prior to screening.~2. Have a known history of substance dependence, or substance (drug) or alcohol abuse~3. Have a significant risk of suicidal or violent behavior.~4. Have a known history of neuroleptic malignant syndrome.~5. Have a known history of long QT syndrome or cardiac tachy-arrhythmia.~6. Have a cancer diagnosis within 3 years of screening (some exceptions allowed)~7. Have received an investigational drug within 30 days prior to screening or plan to use an investigational drug (other than NBI-98854) during the study.~8. Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.~9. Have an allergy, hypersensitivity, or intolerance to tetrabenazine.~10. Have had previous exposure with NBI-98854 or had previously participated in an NBI-98854 clinical study.~11. Are currently pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- NBI-98854 40 mg (Type: EXPERIMENTAL): NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
- NBI-98854 80 mg (Type: EXPERIMENTAL): Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
- Placebo (Type: EXPERIMENTAL): Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.

Based on this trial design, predict the completion outcome and termination type (if applicable).